CytomX Therapeutics Inc (NASDAQ:CTMX) has been given a consensus rating of “Buy” by the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $31.75.
Several research firms recently commented on CTMX. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, January 8th. BidaskClub upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. ValuEngine lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Goldman Sachs Group upgraded shares of CytomX Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, December 13th. Finally, Piper Jaffray Companies began coverage on shares of CytomX Therapeutics in a research report on Sunday, December 2nd. They set an “overweight” rating and a $13.24 price target on the stock.
In other news, CFO Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock in a transaction dated Wednesday, December 12th. The shares were sold at an average price of $15.00, for a total value of $45,000.00. Following the sale, the chief financial officer now owns 8,928 shares in the company, valued at $133,920. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.50% of the stock is owned by company insiders.
CTMX stock opened at $18.97 on Wednesday. The firm has a market cap of $857.84 million, a P/E ratio of -16.35 and a beta of 0.91. CytomX Therapeutics has a one year low of $12.51 and a one year high of $35.00.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: What is the NASDAQ Stock Market?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.